Cytopenia induced by low-dose methotrexate: An analysis of 433 cases from the French pharmacovigilance database.

[1]  Y. Liu,et al.  Associations between the C677T and A1298C polymorphisms of MTHFR and the toxicity of methotrexate in childhood malignancies: a meta-analysis , 2017, The Pharmacogenomics Journal.

[2]  L. Fardet,et al.  Relative risk of and determinants for adverse events of methotrexate prescribed at a low dose: a systematic review and meta‐analysis of randomized placebo‐controlled trials , 2017, The British journal of dermatology.

[3]  S. Ajmani,et al.  Methotrexate‐induced pancytopenia: a case series of 46 patients , 2017, International journal of rheumatic diseases.

[4]  Wei Li,et al.  Lack of association between MTHFR A1298C polymorphism and outcome of methotrexate treatment in rheumatoid arthritis patients: evidence from a systematic review and meta‐analysis , 2017, International journal of rheumatic diseases.

[5]  L. Skov,et al.  Methotrexate Use and Monitoring in Patients with Psoriasis: A Consensus Report Based on a Danish Expert Meeting. , 2017, Acta dermato-venereologica.

[6]  V. Chandran,et al.  Treatment of psoriatic arthritis with traditional DMARD’s and novel therapies: approaches and recommendations , 2017, Expert review of clinical immunology.

[7]  F. Jamali,et al.  Interaction Between Low-Dose Methotrexate and Nonsteroidal Anti-inflammatory Drugs, Penicillins, and Proton Pump Inhibitors , 2017, The Annals of pharmacotherapy.

[8]  A. Dawson,et al.  What can clinicians learn from therapeutic studies about the treatment of acute oral methotrexate poisoning? , 2017, Clinical toxicology.

[9]  F. Marongiu,et al.  Fatal Cytopenia Induced by Low-Dose Methotrexate in Elderly With Rheumatoid Arthritis. Identification of Risk Factors. , 2017, American journal of therapeutics.

[10]  Yuehong Chen,et al.  Are gene polymorphisms related to treatment outcomes of methotrexate in patients with rheumatoid arthritis? A systematic review and meta-analysis. , 2017, Pharmacogenomics.

[11]  R. Warren,et al.  British Association of Dermatologists’ guidelines for the safe and effective prescribing of methotrexate for skin disease 2016 , 2016, The British journal of dermatology.

[12]  A. Malaviya.  Landmark papers on the discovery of methotrexate for the treatment of rheumatoid arthritis and other systemic inflammatory rheumatic diseases: a fascinating story , 2016, International journal of rheumatic diseases.

[13]  A. Lynch,et al.  A decade of Australian methotrexate dosing errors , 2016, The Medical journal of Australia.

[14]  S. Ogston,et al.  Safety and Efficacy of Methotrexate in Psoriasis: A Meta-Analysis of Published Trials , 2016, PloS one.

[15]  K. Migita,et al.  Factors Associated with Myelosuppression Related to Low-Dose Methotrexate Therapy for Inflammatory Rheumatic Diseases , 2016, PloS one.

[16]  R. Caporali,et al.  Methotrexate and Rheumatoid Arthritis: Current Evidence Regarding Subcutaneous Versus Oral Routes of Administration , 2016, Advances in Therapy.

[17]  P. Gisondi,et al.  European S3‐Guidelines on the systemic treatment of psoriasis vulgaris – Update 2015 – Short version – EDF in cooperation with EADV and IPC , 2015, Journal of the European Academy of Dermatology and Venereology : JEADV.

[18]  R. Herbrecht,et al.  Pharmacokinetic drug–drug interactions with methotrexate in oncology , 2011, Expert review of clinical pharmacology.

[19]  B. Haraoui,et al.  Methotrexate Drug Interactions in the Treatment of Rheumatoid Arthritis: A Systematic Review , 2010, The Journal of Rheumatology.

[20]  Y. Lee,et al.  Associations between the C677T and A1298C Polymorphisms of MTHFR and the Efficacy and Toxicity of Methotrexate in Rheumatoid Arthritis , 2010, Clinical drug investigation.

[21]  D. M. van der Heijde,et al.  Long-term safety of methotrexate monotherapy in patients with rheumatoid arthritis: a systematic literature research , 2008, Annals of the rheumatic diseases.

[22]  M. Lapeyre-Mestre,et al.  Pharmacovigilance for evaluating adverse drug reactions: value, organization, and methods. , 2006, Joint, bone, spine : revue du rhumatisme.

[23]  A. Hassell,et al.  The treatment of inflammatory arthritis with methotrexate in clinical practice: treatment duration and incidence of adverse drug reactions. , 2005, Rheumatology.

[24]  Michael R. Cohen,et al.  Reported medication errors associated with methotrexate. , 2004, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.

[25]  E. Hay,et al.  Adverse reactions to disease-modifying anti-rheumatic drugs in clinical practice. , 2001, QJM : monthly journal of the Association of Physicians.

[26]  H. Nygaard.  Pancytopenia secondary to methotrexate therapy in rheumatoid arthritis: comment on the article by Gutierrez-Ureña et al. , 1997, Arthritis & Rheumatism.

[27]  L. Espinoza,et al.  Pancytopenia secondary to methotrexate therapy in rheumatoid arthritis. , 1996, Arthritis and rheumatism.